Glycopyrronium bromide cream for prevention of chronic-relapsing candidiasis of submammary folds: preliminary results of a sponsor-free study

Rossana Schianchib European Institute of Dermatology, Milan, ItalyView further author information

Gianluca Nazzaroc IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyCorrespondence[email protected]
View further author information

References

Masur C, Soeberdt M, Kilic A, et al. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2020;182:1–2.
PubMed Web of Science ®Google Scholar
Abels C, Soeberdt M, Kilic A, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021;185:315–322. doi: 10.1111/bjd.19810.
PubMed Web of Science ®Google Scholar
Gregoriou S, Markantoni V, Campanati A, et al. Treatment of axillary bromhidrosis with topical 2% glycopyrronium bromide cream: a prospective, non-randomized, open-label study. J Clin Aesthet Dermatol. 2021;14: E61–E63.
PubMedGoogle Scholar
Szeimies RM, Abels C, Kilic A, et al. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: results from a phase 3b trial. J Eur Acad Dermatol Venereol. 2023;37(4):823–830. doi: 10.1111/jdv.18843.
PubMed Web of Science ®Google Scholar